Drug Trial Radar · NCT04989803
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
247
Planned (sponsor's estimate)
Start
Oct 27, 2021
Primary completion
Feb 2030
Study completion Feb 2030
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Conditions
- Relapsed and/or Refractory B-cell Lymphoma
Interventions
CyclophosphamideDrug
Lymphodepleting chemotherapy administered intravenously
FludarabineDrug
Lymphodepleting chemotherapy administered intravenously
KITE-363Biological
A single infusion of CAR-transduced autologous T cells administered intravenously
KITE-753Biological
A single infusion of CAR-transduced autologous T cells administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753Time frame: Up to 28 days
- Phase 1b: Objective Response Rate (ORR) for KITE-363 and KITE-753 as per investigator's assessment.Time frame: Up to 24 months
- Phase 2: ORR as per central assessment for KITE-753Time frame: Up to 36 months
Locations
36 sites in 6 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California
Stanford Cancer Institute
Stanford, California
Mayo Clinic Jacksonville
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
Northside Hospital
Atlanta, Georgia
University of Illinois Chicago
Chicago, Illinois
Midwestern Regional Medical Center, Inc.City of Hope Chicago
Park Ridge, Illinois
Norton Cancer Institute, St. Matthews Campus
Shelbyville, Kentucky
University of MD, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Mayo Clinic
Rochester, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Columbia University Irving Medical Center
New York, New York
University of Rochester Medical Center
Rochester, New York
The Ohio State University Wexner Medical Center - James Cancer Hospital
Columbus, Ohio
Tennessee Oncology, PLLC - Investigational Drug Services
Nashville, Tennessee
Vanderbilt University
Nashville, Tennessee
St. David's Medical Center
Austin, Texas
The University of Texas, MD Anderson Cancer Center
Houston, Texas
Virginia Oncology Associates
Norfolk, Virginia
Swedish Cancer Institute
Seattle, Washington
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Concord Repatriation General Hospital
Sydney, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Monash Health, Monash Medical Centre
Clayton, Victoria, Australia
Epworth Healthcare
East Melbourne, Victoria, Australia
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
Cross Cancer Center
Edmonton, Canada
Queen Elizabeth II Health Sciences Centre
Halifax, Canada
Jewish General Hospital
Montreal, Canada
McGill University Health Center
Montreal, Canada
Princess Margaret Cancer Centre - University Health Network
Toronto, Canada
Universitatsklinikum Wurzburg
Würzburg, Germany
Academisch Medisch Centrum
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Netherlands
King's College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.